OSLO, Norway, December 23, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA NYKDa clinical-stage biopharmaceutical company devoted to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer, Michael Engsig, will be present at the 41st Annual JP Morgan on Monday, January 9, 2023 at 1:30 p.m. PT Healthcare Conference will give a presentation. 22:30 CET.

The live and archived webcast of the presentation can be accessed on the Investors section of the Company’s website here.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company devoted to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens on antigen-presenting cells, which are essential for inducing rapid, powerful and long-lasting antigen-specific immune responses and triggering effective clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of malignancies caused by human papillomavirus (HPV)-16, which has demonstrated positive preliminary efficacy and safety results from its Phase 2 study in the treatment of cervical cancer; and VB10.NEO, a personalized cancer neoantigen vaccine exclusively licensed to Genentech, a member of the Roche Group. In addition, Nykode is conducting a phase 1/2 trial of next-generation COVID-19 vaccine candidates.

The company’s partnerships include Genentech in oncology, a multi-target collaboration with Regeneron in oncology and infectious diseases, and a collaboration with Adaptive Biotechnologies for COVID-19 T-cell vaccine development.

Nykode Therapeutics shares are traded on the Oslo Stock Exchange NYKD. For more information on Nykode Therapeutics, visit http://www.nykode.com

Contact for Nykode Therapeutics ASA:

Manager Agnete Fredriksen
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA

Oslo…